Elevance Health stock edges toward $400 as Q2 2026 earnings and guidance support valuation

Elevance Health Inc. (ISIN US2855211023) stock is trading close to the $400 threshold as of August 21, 2026, backed by solid second quarter earnings and a higher full-year 2026 guidance for adjusted earnings per share.

Per an earnings call transcript for the quarter ended June 30, 2026, Elevance Health reported adjusted diluted earnings per share of $7.45 and operating revenue of $49.8 billion, and management raised its 2026 adjusted EPS guidance to at least $27, signaling confidence in double-digit earnings growth into 2027. The Q2 2026 earnings call transcript also highlighted strong operating cash flow of $1.9 billion and 44.9 million medical members at quarter end.

Q2 2026 earnings and guidance reset

The latest quarterly figures give investors a detailed picture of Elevance Health's financial performance in Q2 2026, which ended on June 30, 2026.

Operating revenue in the quarter came in at $49.8 billion, representing a 0.8 percent increase compared with the same period a year earlier, supported by higher premium yields and product revenue that offset lower health plan membership. The Q2 2026 operating overview notes that adjusted diluted EPS of $7.45 compared with $8.84 in the prior-year quarter, reflecting a lower reported earnings level but still comfortably ahead of the firm's internal outlook.

Management used the Q2 2026 release to raise full-year 2026 adjusted diluted EPS guidance to at least $27 per share, up from the prior outlook, and reiterated that it aims to deliver at least 12 percent adjusted EPS growth in 2027 off the 2026 baseline. The guidance section of the Q2 2026 call links the improved outlook to favorable benefit expense performance, disciplined cost management, and ongoing efforts to manage healthcare costs more effectively across the enterprise.

In the balance sheet and cash flow discussion for the quarter, Elevance Health reported days in claims payable of 45.4 days as of June 30, 2026, an increase of 2.9 days year over year, and operating cash flow of $1.9 billion, supported by strong operating performance and the timing of a state Medicaid pass-through payment. The same Q2 2026 commentary indicates that Medicaid margins are tracking within the full-year framework laid out earlier in 2026.

Membership mix and segment dynamics

Beneath the headline earnings and revenue figures, Elevance Health's Q2 2026 results included several important operational metrics that help explain the company's positioning in major segments.

The company ended the quarter with 44.9 million medical members, with sequential changes driven by a known fee-based customer transition and attrition in individual ACA and Medicaid plans. The Q2 2026 membership overview points out that operating outperformance of roughly $0.50 per share was split between Medicare Advantage and individual ACA, indicating that management's portfolio actions and care management initiatives are delivering tangible financial benefits in these lines of business.

Commentary from a sector-focused article comparing large managed care firms highlights that Elevance Health is sharpening its Medicare Advantage strategy by prioritizing profitable growth rather than broad membership expansion, with a stronger focus on dual-eligible and HMO offerings and care management initiatives that support a path toward at least a 2 percent operating margin in 2026. A recent managed care industry comparison notes that favorable claims trends and disciplined plan design are helping Elevance Health navigate reimbursement changes while supporting its guidance.

Elevance Health's exposure to government programs remains significant, with Q2 2026 commentary indicating that Medicaid performance during the quarter is tracking within the previously communicated margin framework and that the timing of pass-through payments continues to influence quarterly cash flow patterns. The discussion of Medicaid and cash flow suggests that management is balancing margin objectives with member retention as states continue eligibility redeterminations.

Analyst consensus and valuation context

Beyond the company's internal guidance, the external analyst view provides another benchmark for Elevance Health's valuation and expected earnings trajectory through the remainder of 2026.

Data compiled from analyst coverage indicates that Elevance Health currently carries an average rating of moderate buy and a consensus target price of $440.90 per share, implying upside of more than 10 percent from recent trading levels in the high $390 to low $400 range. One recent analyst-consensus overview reports the same $440.90 average target and outlines institutional interest in the stock, while another consensus snapshot confirms the moderate buy rating and target level from a separate dataset.

A quantitative earnings summary indicates that Elevance Health's Q2 2026 revenue of $49.83 billion represented a 0.8 percent year-over-year increase, and EPS of $7.45 was down from $8.84 in the prior-year period, consistent with the figures shared in the earnings call. The earnings summary for the June 2026 quarter also notes that Elevance Health is expected to post earnings of $4.82 per share for the current quarter, representing a projected decline of 20.1 percent year over year, with consensus estimates having shifted modestly lower over the past month.

Given management's guidance of at least $27 adjusted EPS in 2026 and a recent share price close to $397.15 as of August 21, 2026, Elevance Health's stock trades at a forward price-to-earnings ratio near 14.7 times the full-year guidance. A valuation-focused commentary on Elevance Health highlights that this multiple sits in the mid-teens and compares it with sector peers, suggesting that the combination of modest revenue growth, cash flow strength and a targeted Medicare Advantage margin profile underpins the stock's current valuation.

Dividend metrics further round out the investment case. A dividend-focused snapshot shows Elevance Health's share price at $401.09 during intraday trading on August 21, 2026, with a dividend yield of roughly 1.72 percent to 1.73 percent based on an annual dividend of $6.88 per share, reflecting a balance between capital returns and reinvestment in growth initiatives. The dividend and intraday quote overview for ELV provides this yield range and underscores the company's consistent capital return policy.

Care programs and health outcomes initiatives

Beyond earnings and valuation, Elevance Health is also involved in programs that link benefit design and social determinants of health to measurable outcomes, which can have longer-term implications for cost trends and member engagement.

A study highlighted in a managed care journal analyzed health plan members with type 2 diabetes who enrolled in an Elevance Health plan offering between $1,200 and $3,000 annually in grocery assistance, finding an associated 3.1 percentage point decrease in the prevalence of diabetes with complications and improved adherence to diabetes medications, without any corresponding increase in overall healthcare utilization. The referenced diabetes outcomes study suggests that benefit programs targeting food security can support better clinical outcomes and may over time influence claims trends and pharmacy adherence patterns for affected members.

For investors, such programs underline a broader care management strategy that goes beyond traditional benefit design, with potential to reinforce Elevance Health's operating performance by moderating complication rates and keeping members engaged in preventive and chronic care. As the company continues to focus on managing healthcare costs across the enterprise, data-driven interventions that show measurable improvements in outcomes can complement margin frameworks in key segments like Medicare Advantage and Medicaid.

Representative offering: grocery assistance benefits

One representative Elevance Health offering that connects directly to the outcomes research is its grocery assistance benefit for eligible members with chronic conditions such as type 2 diabetes.

In the studied plans, members could receive annual grocery assistance between $1,200 and $3,000, structured to support access to healthy food and adherence to recommended diets for diabetes management. The examination of Elevance Health's grocery benefit reports that the program was associated with lower prevalence of diabetes with complications and better medication adherence, suggesting that such benefits can act as a complement to traditional medical and pharmacy coverage and may ultimately help stabilize long-term healthcare costs.

As Elevance Health refines its care management strategies in 2026 and beyond, offerings that target social determinants of health, such as nutrition support, are likely to remain an important part of the portfolio, particularly in government programs and value-based arrangements where improved outcomes can translate into more predictable cost patterns.

Elevance Health stock and market backdrop

Elevance Health stock trades on the New York Stock Exchange under the ticker ELV, and recent market data show the shares hovering just below the $400 mark in regular trading on August 21, 2026.

Price data from an equity commentary indicate that the stock was quoted at around $397.15 per share on August 21, 2026, leaving it only a short distance from the psychologically significant $400 level. The discussion of Elevance Health's share price and chart context notes that the current valuation combined with raised 2026 guidance yields a forward price-to-earnings ratio near 14.7, which some investors may view as a reasonable multiple for a large managed care firm with modest revenue growth and targeted margin improvements.

For US retail investors considering Elevance Health in the broader healthcare and managed care landscape, the key numbers now include Q2 2026 operating revenue of $49.8 billion, adjusted diluted EPS of $7.45 with guidance of at least $27 for full-year 2026, a consensus target price of $440.90, and a dividend yield near 1.7 percent, all set against a share price currently in the high $390 to low $400 range. These figures frame the stock's current positioning and highlight how earnings, guidance, analyst views and capital returns intersect at today's valuation.

Go deeper

More on Elevance Health stock, including archived news and additional market data, can be found on the Elevance Health NYSE:ELV overview pages of major financial portals and in the company's own investor materials.

Fact box

Company: Elevance Health Inc.

ISIN: US2855211023

Ticker: ELV

Exchange: NYSE

Market cap: Derived from a share price in the high $390 to low $400 range and guidance of at least $27 adjusted EPS for 2026, implying a forward price-to-earnings ratio near 14.7.

Sector / Industry: Health care - Managed care and health benefits

Index membership: S&P 500